The global insulin drugs and delivery devices market size is calculated at USD 23.75 billion in 2024, grew to USD 25.58 billion in 2025, and is projected to reach around USD 49.18 billion by 2034. The market is expanding at a CAGR of 7.65% between 2025 and 2034.
Key players, such as Abbott Laboratories, Eli Lilly & Company, and MannKind Corporation, are major manufacturers and suppliers of insulin drugs and delivery devices in the U.S. It is estimated that more than 38.4 million Americans rely on insulin for the management of diabetes. The U.S. government’s Healthy People 2030 aims to reduce diabetes cases, complications, and deaths.
The federal government’s next step toward the first phase of national universal pharmacare is the introduction of Bill C-64 into Parliament, and the intention to provide universal, single-payer coverage for various diabetes medications. Statisque Canada reported that the prevalence of diabetes is around 1% in Canadians aged 20 to 39 years, and about 1 in 5 seniors aged 60 to 79 years.
IDF reported that the prevalence of diabetes is 11.9% in China, affecting over 147 million people. China has a suitable manufacturing infrastructure, encouraging foreign players to set up their manufacturing facilities. In December 2024, Sanofi announced an investment of around 1 billion euros ($1.1 billion) to build a new insulin production base in Beijing.
More than 89 million people, or 10.5% of the population, in India have diabetes. The diabetes sector has 41 companies in India, including 19 funded companies. These 19 companies have collectively raised $78.1 million in venture capital and private equity. India’s Ministry of Health and Family Welfare (MoHFW) collaborated with the WHO and WDF to provide timely access to care for people with diabetes and hypertension by 2025.
R&D activities refer to developing insulin formulations with improved pharmacokinetic properties. They also involve developing novel delivery systems to automate insulin delivery.
Key Players: Sanofi, Eli Lilly and Company, and Novo Nordisk.
Regulatory agencies mandate companies to conduct clinical trials for novel insulin drugs and delivery devices to assess their safety and efficacy.
Key Players: Wockhardt, Biodel, MannKind Corporation, and Sanofi.
Manufacturers sell insulin drugs and delivery devices to distributors or wholesalers through a regulated supply chain and a favorable logistics infrastructure.
Key Players: Biocon, Durbin, and IDA Foundation.
Patient support & services refer to educating patients about diabetes diagnosis and treatment, including insulin dosage. Healthcare professionals also respond to complications associated with insulin drugs.
Dr. Marc Breton, Associate Director for Research at the UVA Center for Diabetes Technology, commented that after working with Tandem for more than 10 years, the expansion of collaboration marks a new beginning to serve patients with diabetes. Together, both will expand their research efforts into automated insulin delivery with the goal of once more substantially enhancing care and quality of life for patients globally.
Become a valued research partner with us, please feel free to contact us at sales@towardshealthcare.com
